Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
50.56%
Operating Margin
47.94%
Net Margin
22.89%
Efficiency Metrics
Revenue per Expense Ratio
1.92
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
48.01%
Income Tax Rate
19.01%
EPS
3.7400000000
Balance Sheet Analysis
Current Ratio
0.96
Cash Ratio
0.19
Working Capital
$-268.00M
Debt to Equity
0.31
Debt to Assets
16.26%
Equity Ratio
52.44%
Cash Flow Analysis
Operating Cash Flow Ratio
34.34%
Free Cash Flow Ratio
20.70%
CapEx to Revenue
13.65%
Dividends Paid
$3.89B
Stock Buybacks
$3.32B
Total Shareholder Returns
$7.21B
Cash Position Change
-4.67%
Key Takeaways (2023 FY)
Revenue declined by 27.38138501918%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-27.38%
Net Income
-24.72%
EPS
-22.41%
Operating Income
16.82%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
-22.64%
Operating Cash Flow
-36.30%
Free Cash Flow
-47.90%
Balance Sheet Health
Assets
-0.25%
Debt
7.94%
Book Value per Share
7.45%
Inventory
12.07%
Shareholder Returns
Dividends per Share
-18.66%
Shares Outstanding
-2.89%
Long Term Trends
3Y Revenue/Share
120.49%
5Y Revenue/Share
78.51%
3Y Dividend/Share
113.95%
5Y Dividend/Share
175.47%